Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy

Hepatology

Volumn 29, Issue 1, 1999, Pages 264-270

  Bonkovsky, Herbert L ^a   Wolley, Michael ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; BLOOD SAMPLING; CHRONIC DISEASE; DRUG EFFECT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; QUALITY OF LIFE;

EID: 0032934283     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510290124     Document Type: Article

References (20)

1. Alter MJ. Epidemiology of hepatitis C. HEPATOLOGY 1997;26(Suppl):62S-65S.
2. Seeff LB. Natural history of hepatitis C. HEPATOLOGY 1997;26(Suppl):21S-28S.
3. Alter HJ, Loury-Cantilena C, MelpolderJ, Tan D, Van Raden M, Henrion D, Lau D, et al. Hepatitis C in asymptomatic blood donors. HEPATOLOGY 1997;26(Suppl):29S-33S.
4. Ware JE, Bungay K, Gandek B, Bayliss M. Assessment of the health-related quality of life (HQL) of patients with chronic hepatitis C (CHC). Gastroenterology 1994;106:A393.
5. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, et al. Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clin Ther 1994;16:334-343.
6. Carithers RL, Sugano D, Bayliss M. Health assessment for chronic HCV infection. Dig Dis Sci 1996;41(Suppl):75S-80S.
7. Bayliss M, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE Jr. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998;7:39-55.
8. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. HEPATOLOGY 1998;27:209-212.
9. Hunt C, Dominitz J, Bute BP, Waters B, Blasi U, Williams D. Effect of interferon treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997;42:2482-2486.
10. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keefe EB, Hollinger FB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. HEPATOLOGY 1997;26:747-754.
11. Davis GA, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 1989;321:1501-1506.
12. 2b for 60 weeks. HEPATOLOGY 1994;19:280-285.
13. Poynard T, Leroy V, Cohard M, Thvenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. HEPATOLOGY 1996;24:778-789.
14. Carithers RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. HEPATOLOGY 1997;26(Suppl):83S-88S.
15. Romeo R, Pol S, Berthelot P, Brechet C. Eradication of hepatitis C virus RNA after alpha-interferon therapy. Ann Intern Med 1994;121:276-277.
16. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, Yun Z-B, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. HEPATOLOGY 1995;21:918-922.
17. Marcellin P, Boyer N, Gervais A, Martinet M, Pouteau M, Castelnau C, Kilani A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997;127:875-881.
18. Thalji L, Haggerty CC, Rubin R, Berckmans TR, Pardee BL. 1990 National Survey of Functional Health Status: Final Report. Chicago, IL: National Opinion Research Center, 1991.
19. Stewart AL, Ware Jr. JE. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press, 1992.
20. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care 1992;30:473-483.